|Mr. James R. Neal||CEO & Director||679.85k||N/A||1956|
|Mr. Thomas M. Burns||Sr. VP of Fin. & CFO||467.39k||N/A||1974|
|Mr. Danny J. Hart Jr.||VP & Gen. Counsel||N/A||N/A||1976|
XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy. The company also licenses antibody discovery, optimization, and development technologies. It has research and development collaboration agreements with Novartis Vaccines and Diagnostics, Inc.; Novartis Pharma AG; Novartis International Pharmaceutical Ltd.; Rezolute, Inc.; and Takeda Pharmaceutical Company Limited. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
XOMA Corporation’s ISS Governance QualityScore as of October 4, 2019 is 6. The pillar scores are Audit: 1; Board: 7; Shareholder Rights: 2; Compensation: 10.